首页> 外文期刊>Journal of the Siena Academy of Sciences >GENETIC OF THYROID CANCER MOLECULAR ANALYSIS OF FINE NEEDLE ASPIRATION SAMPLES TO REFINE THE DIAGNOSIS OF THYROID CANCER
【24h】

GENETIC OF THYROID CANCER MOLECULAR ANALYSIS OF FINE NEEDLE ASPIRATION SAMPLES TO REFINE THE DIAGNOSIS OF THYROID CANCER

机译:甲状腺癌的分子遗传学分析细针抽吸样品的分子分析以重新确定甲状腺癌的诊断

获取原文
       

摘要

Fine Needle Aspiration Cytology (FNAC) is the gold standard for the differential diagnosis of thyroid nodules, but has the limitation of inadequate sampling or indeterminate lesions. Our Unit of Endocrinology was involved in a pilot study aimed to verify whether search of thyroid cancer-associated proto-oncogene mutations in cytological samples may improve the diagnostic accuracy of FNAC. Our results demonstrated that the presence of mutations at cytology was associated with cancer 91.1% of the times and with follicular adenoma 8.9% of the times. BRAF or RET/PTC mutations were always associated with cancer, while RAS mutations were mainly associated with cancer (74%) but also with follicular adenoma (26%). The diagnostic performance of molecular analysis was superior to that of traditional cytology, with better sensitivity and specificity, and the combination of the two techniques further contributed to improve the total. At the moment, we have introduced the search for the most common mutations (BRAF, 3 RAS isoforms and RET/PTC rearrangements) in the clinical practice especially in those FNAC which resulted indeterminate at the first cytological analysis.
机译:细针穿刺细胞学(FNAC)是甲状腺结节鉴别诊断的金标准,但局限性在于取样不充分或病灶不确定。我们的内分泌科参与了一项试点研究,目的是验证在细胞学样本中搜索甲状腺癌相关原癌基因突变是否可以提高FNAC的诊断准确性。我们的结果表明,细胞学上突变的存在与癌症的发生率分别为91.1%和8.9%与滤泡性腺瘤相关。 BRAF或RET / PTC突变总是与癌症有关,而RAS突变主要与癌症有关(74%),但也与滤泡性腺瘤(26%)有关。分子分析的诊断性能优于传统细胞学,具有更高的灵敏度和特异性,两种技术的结合进一步提高了分析效率。目前,我们已经介绍了在临床实践中寻找最常见的突变(BRAF,3个RAS亚型和RET / PTC重排)的方法,特别是那些在第一次细胞学分析中导致不确定的FNAC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号